SCHEMBL1447712

SCHEMBL1447712

Cc1c[c]ccc1NC(=O)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 2/20 0.46
TP53 P04637 2/20 0.46
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CETP P11597 1/20 0.44
PGR P06401 1/20 0.41
SCN1A P35498 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN3A Q9NY46 1/20 0.41
MDM2 Q00987 1/20 0.41
LMNA P02545 3/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 1/20 0.40
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2900761 0.88 MDM4 (0.47) MDM4TP53GAAL3MBTL1CETP
SCHEMBL1452105 0.86 MDM4 (0.49) MDM4TP53GAAL3MBTL1CETP
SCHEMBL22683489 0.81 MDM4 (0.45) MDM4TP53GAAL3MBTL1CETP
SCHEMBL6205970 0.80 ALDH1A1 (0.55) GAAMAPTHPGDALDH1A1MEN1
SCHEMBL1569951 0.79 HTT (0.46) MDM4TP53GAAMAPTHPGD
SCHEMBL1477556 0.78 MDM4 (0.45) MDM4TP53GAAL3MBTL1CETP
SCHEMBL2903333 0.78 MEN1 (0.48) MDM4TP53GAAL3MBTL1CETP
SCHEMBL11323383 0.77 ALDH1A1 (0.50) TP53L3MBTL1LMNAMAPTHPGD
SCHEMBL1447993 0.76 L3MBTL1 (0.46) TP53L3MBTL1CETPLMNAMAPT
SCHEMBL2902879 0.76 HTT (0.46) MDM4TP53GAACETPMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4262851-A HIGH SPEED MILLING WITHOUT SURFACTANTS BASF AKTIENGESELLSCHAFT (DE) 1981-04-21 US claimed
WO-2023134708-A1 THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS BEIGENE , LTD. (KY) 2023-07-20 WO disclosed
WO-2011030139-A1 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS ASTRAZENECA AB (SE) 2011-03-17 WO disclosed
US-20110065706-A1 Therapeutic Agents 812 ASTRAZENECA AB (SE) 2011-03-17 US disclosed
US-4262851-A HIGH SPEED MILLING WITHOUT SURFACTANTS BASF AKTIENGESELLSCHAFT (DE) 1981-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065706-A1 Therapeutic Agents 812 GPR119, GPR84, GPR132 MDM4 4883/4885TP53 4565/4885GAA 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.